Tissue factor in COVID-19-associated coagulopathy

Subramaniam, Saravanan; Kothari, Hema; Bosmann, Markus

doi:10.1016/j.thromres.2022.09.025

Cited by 25 publications

(15 citation statements)

References 280 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The identified biomarkers are real and reflect the biology of viral infections which do activate the inflammasome, leading to the production of important cytokines/chemokines (IL-1β, TNF-α, IL-6, etc.) (37,38). This may be the main reason why existing studies predominantly measured only these main inflammatory biomarkers.…”

Section: Strengths and Weaknesses Of The Researchmentioning

confidence: 99%

Biomarkers in long COVID-19: A systematic review

et al. 2023

View full text Add to dashboard Cite

PurposeLong COVID, also known as post-acute sequelae of COVID-19, refers to the constellation of long-term symptoms experienced by people suffering persistent symptoms for one or more months after SARS-CoV-2 infection. Blood biomarkers can be altered in long COVID patients; however, biomarkers associated with long COVID symptoms and their roles in disease progression remain undetermined. This study aims to systematically evaluate blood biomarkers that may act as indicators or therapeutic targets for long COVID.MethodsA systematic literature review in PubMed, Embase, and CINAHL was performed on 18 August 2022. The search keywords long COVID-19 symptoms and biomarkers were used to filter out the eligible studies, which were then carefully evaluated.ResultsIdentified from 28 studies and representing six biological classifications, 113 biomarkers were significantly associated with long COVID: (1) Cytokine/Chemokine (38, 33.6%); (2) Biochemical markers (24, 21.2%); (3) Vascular markers (20, 17.7%); (4) Neurological markers (6, 5.3%); (5) Acute phase protein (5, 4.4%); and (6) Others (20, 17.7%). Compared with healthy control or recovered patients without long COVID symptoms, 79 biomarkers were increased, 29 were decreased, and 5 required further determination in the long COVID patients. Of these, up-regulated Interleukin 6, C-reactive protein, and tumor necrosis factor alpha might serve as the potential diagnostic biomarkers for long COVID. Moreover, long COVID patients with neurological symptoms exhibited higher levels of neurofilament light chain and glial fibrillary acidic protein whereas those with pulmonary symptoms exhibited a higher level of transforming growth factor beta.ConclusionLong COVID patients present elevated inflammatory biomarkers after initial infection. Our study found significant associations between specific biomarkers and long COVID symptoms. Further investigations are warranted to identify a core set of blood biomarkers that can be used to diagnose and manage long COVID patients in clinical practice.

show abstract

Section: Strengths and Weaknesses Of The Researchmentioning

confidence: 99%

Biomarkers in long COVID-19: A systematic review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…We</ins> <del cite="mailto:User" datetime="2022-12-18T21 : 04">and</del> were unable to include some potentially interesting novel biomarkers, that are currently used only for research purposes. <ins cite="mailto:User" datetime="2022-12-18T21 : 04"></ins><ins cite="mailto:User" datetime="2022-12-18T21 : 05">This to be said several studies have identified endothelial dysfunction and markers of extrinsic coagulation pathway</ins> <ins cite="mailto:User" datetime="2022-12-18T21 : 06">to have an important role in</ins> <ins cite="mailto:User" datetime="2022-12-18T21 : 07">the pathophysiology of</ins> <ins cite="mailto:User" datetime="2022-12-18T21 : 06">hypercoagulation</ins> <ins cite="mailto:User" datetime="2022-12-18T21 : 10">as well as a potential prognostic impact</ins> <ins cite="mailto:User" datetime="2022-12-18T21 : 06">in Covid-19</ins> <ins cite="mailto:User" datetime="2022-12-18T21 : 07"></ins> [38][39][40]<ins cite="mailto:User" datetime="2022-12-18T21 : 06">.</ins> However, since our goal was to investigate the correlation of common biomarkers with VTE in clinical practice, we are convinced that it was a drawback of minor entity.…”

Section: U N C O R R E C T E D a U T H O R P R O O Fmentioning

confidence: 99%

Predictive value of inflammatory and coagulation biomarkers for venous thromboembolism in COVID-19 patients

Hojker

Tršan

et al. 2023

View full text Add to dashboard Cite

BACKGROUND: The predictive value of coagulation markers for venous thromboembolism (VTE) in Covid-19 patients has been investigated with conflicting results. OBJECTIVE: Our aim was to investigate the correlation between biomarkers and VTE and the predictive value of D-dimer for VTE in hospitalized Covid-19 patients. METHODS: Complete blood count, inflammatory and coagulation biomarkers at admission were collected. VTE was defined as diagnosed pulmonary embolism or deep vein thrombosis. Events were defined as in-hospital death or ICU admission. Predictors of VTE were identified with Pearson prediction models. A ROC curve was constructed to assess the predictive value of D-dimer. RESULTS: 1651 participants were included, 111 VTE were identified. Events incidence was higher in the VTE group (49.5% vs 28.2%, p < 0.001). Neutrophil-lymphocyte ratio (NLR, 0.001; 95% CI 0.000–0.002; p 0.019) and D-dimer (0.00005; 95% CI 0.00002–0.00008; p < 0.001), Geneva score (0.026; 95% CI 0.012–0.040; p < 0.001) and Wells score (0.047; 95% CI 0.033–0.061; p < 0.001) were associated with VTE. D-dimer had a goor predictive value for VTE (ROC area 0.85, 95% CI 0.816–0.893), with an optimal cut-off value of 2677μg/L (Youden index of 0,602). CONCLUSIONS: Among coagulation biomarkers D-dimer had the best predictive value for VTE, but higher cut-off values should be used in Covid-19.

show abstract

“…To fill this gap, in this study we have performed flow cytometric and multiomics analyses of blood samples obtained from COVID-19 patients, with or without neoplastic disease. While cancer and COVID-19 share an elevated risk of thrombosis, with increased D-dimer levels ( 82 ), we show that the co-existence of neoplasia and COVID-19 inhibits the upregulation of the inflammatory biomarkers CRP and D-dimer, notoriously associated with COVID-19 severity ( 1 , 19 , 20 ), suggesting that the reduced expression of IL-6 observed in COV/CA PBMCs may result in reduced tissue factor levels ( 83 ) and thus in the concomitant reduction of D-dimer levels.…”

Section: Discussionmentioning

confidence: 81%

Immunometabolic interference between cancer and COVID-19

et al. 2023

View full text Add to dashboard Cite

Even though cancer patients are generally considered more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the mechanisms driving their predisposition to severe forms of coronavirus disease 2019 (COVID-19) have not yet been deciphered. Since metabolic disorders are associated with homeostatic frailty, which increases the risk of infection and cancer, we asked whether we could identify immunometabolic pathways intersecting with cancer and SARS-CoV-2 infection. Thanks to a combined flow cytometry and multiomics approach, here we show that the immunometabolic traits of COVID-19 cancer patients encompass alterations in the frequency and activation status of circulating myeloid and lymphoid subsets, and that these changes are associated with i) depletion of tryptophan and its related neuromediator tryptamine, ii) accumulation of immunosuppressive tryptophan metabolites (i.e., kynurenines), and iii) low nicotinamide adenine dinucleotide (NAD+) availability. This metabolic imbalance is accompanied by altered expression of inflammatory cytokines in peripheral blood mononuclear cells (PBMCs), with a distinctive downregulation of IL-6 and upregulation of IFNγ mRNA expression levels. Altogether, our findings indicate that cancer not only attenuates the inflammatory state in COVID-19 patients but also contributes to weakening their precarious metabolic state by interfering with NAD+-dependent immune homeostasis.

show abstract

Tissue factor in COVID-19-associated coagulopathy

Cited by 25 publications

References 280 publications

Biomarkers in long COVID-19: A systematic review

Biomarkers in long COVID-19: A systematic review

Predictive value of inflammatory and coagulation biomarkers for venous thromboembolism in COVID-19 patients

Immunometabolic interference between cancer and COVID-19

Contact Info

Product

Resources

About